US-based biopharma Anthera Pharmaceuticals (Nasdaq: ANTH) has appointed Chuck Olson as president of its subsidiary Alkira Therapeutics.
He will oversee development activities for the company’s exocrine pancreatic insufficiency drug Sollpura (liprotamase), including product manufacturing for the upcoming Phase III clinical trial, which will begin mid-2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze